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Gut mucosal damage or mucositis, often experienced by cancer
patients as a result of chemotherapy or radiotherapy, can be so
severe as to be dose-limiting in the treatment regimens and be
the major reason for the patient’s hospitalization (Costa and
Donaldson, 1979). While the mucosal damage is known to be
induced initially as a consequence of a loss of cell mitosis in the
epithelium (Trier, 1962; Altmann, 1974), leading to flattening of
the villi and absorptive dysfunction (Donaldson and Lenon, 1979),
the mechanisms for the subsequent mucosal regeneration remain
largely unknown. The current study aimed to examine the relation-
ship between the expression of hepatocyte growth factor (HGF)
and its receptor c-met, molecules previously implicated in
intestinal tissue repair, with the histopathological and proliferative
changes of the intestine in a rat model of methotrexate-induced
intestinal mucositis.
HGF is a potent morphogen, motogen and mitogen for a diverse
variety of epithelial cells (Schmassmann et al, 1997a). Previous
studies have demonstrated the mRNA and protein expression of
HGF and c-met in various tissues, including the developing diges-
tive tissues (Wang et al, 1994; Kermorgant et al, 1997) and the
normal adult stomach, small intestine and colon (Di Renzo et al,
1991; Prat et al, 1991; Wolf et al, 1991). HGF accelerated repair 
of gastric epithelium, protected against ethanol-induced gastric
epithelial injury (Takahashi et al, 1996) and stimulated mucosal
regeneration and functional recovery after massive small bowel
resection (Kato et al, 1998). As a step to investigate potential roles
of HGF in enhancing intestinal repair in chemotherapy-induced
intestinal mucositis, the expression of HGF and its receptor was
examined in association with the morphological and proliferative
changes in methotrexate-induced small intestinal damage and
repair in the rat. Methotrexate, an anti-metabolite used for
neoplastic treatment regimens, inhibits the enzyme dihydrofolate
reductase. The reduced availability of intracellular folate impairs
DNA synthesis (Jolivet et al, 1983). The methotrexate-induced
intestinal mucositis in rats is characterized histologically by crypt
loss, villus fusion and atrophy, capillary dilatation, and a mixed
inflammatory cellular infiltrate (Taminiau et al, 1980; Howarth et
al, 1996), resembling the gut mucositis experienced as a common
side-effect by patients undergoing chemotherapy or radiotherapy
(Altmann, 1974).
MATERIALS AND METHODS
Methotrexate time course and intestinal tissue
collection
Intestinal mucositis was induced in male adult Sprague Dawley
rats by subcutaneous injection in the suprascapular region of
methotrexate at a dose of 2.5mg kg–1 once daily for up to 3
consecutive days (Howarth et al, 1996). The rats were maintained
ad libitum up to day 10 after the first injection. Rats without
methotrexate injection were used as normal controls (day 0). On
each day after the first injection, groups of rats (n= 8) were
injected intraperitoneally (i.p.) with bromodeoxyuridine (BrdU) at
50mg kg–1 and sacrificed 1h later by carbon dioxide overdose.
Two groups of pair-fed control rats (n= 4), which received no
methotrexate injection but consumed similar daily amounts of diet
to the methotrexate-injected animals, were killed on day 5 and day
8 for comparison with their methotrexate-injected counterparts.
Specimens from the proximal jejunum were freshly collected,
either snap-frozen and stored at –80°C, or fixed in methacarn
fixative for 2h prior to routine processing for paraffin-embedding.
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All these procedures were approved by the Animal Ethics
Committee of the Women’s and Children’s Hospital, Adelaide,
Australia.
Histopathological analysis of intestinal damage and
repair
Transverse sections (4 mm in thickness) of paraffin-embedded
proximal jejunal specimens were stained with haematoxylin and
eosin (H&E) and examined with a light microscope. A semi-quan-
titative histological assessment of intestinal damage was utilized
to obtain an overall score of damage severity. A total score for the
sample was derived from the sum of scores for 11 histopatholog-
ical criteria as we have previously described (Howarth et al, 1996),
including villus fusion and stunting (atrophy), disruption of brush
border and surface enterocytes, disappearance of goblet cells,
reduction in numbers of mitotic figures, crypt loss/architectural
disruption, disruption or distortion of crypt cells, crypt abscess
formation, infiltration of polymorphonuclear cells and lympho-
cytes and dilatation of lymphatics and capillaries. For each crite-
rion, a score was given to represent a mild (score 1), moderate (2),
severe (3), or no (0) changes.
Quantitative histological analyses were also conducted to
measure the changes in crypt depth and villus height in the jejunal
specimens over the time course. Microscopic images were
acquired and analysed. For each animal, the height and depth of
ten villi and crypts respectively were measured at three tissue
levels, each separated by 100 mm, and means of the 30 measure-
ments were calculated for each animal. Although histological
damage prevented accurate measurements of villus and crypt
lengths in some regions, in the jejunal region where these
measurements were made at least 50% of mucosal area was suffi-
ciently intact for reliable determination of villus height and crypt
depth at the time with maximal damage.
BrdU labelling and cell counting
BrdU labelling was used to assess cell proliferation in the jejunal
tissues. Immunostaining of BrdU was performed on 3-mm paraffin
sections as previously described (Fox et al, 1996) with a mouse
anti-BrdU IgG as the primary antibody, a rabbit anti-mouse
biotinylated IgG as the secondary antibody, and avidin and
biotinylated horseradish peroxidase reagents and diaminobenzi-
dine tetrahydrochloride as enzyme/substrate reagents (Dako,
Carpinteria, CA, USA). BrdU labelling index was determined by
counting the numbers of positive and the total number of crypt
epithelial cells. For each animal, 50 well-orientated full crypts
were analysed, and the number of BrdU-labelled cells and the total
number of crypt epithelial cells on the left-side halves of the crypts
were counted. The number of positive cells was expressed as a %
of the total number of epithelial cells to provide the labelling index
for that crypt, and the mean of the 50 crypts was calculated as the
labelling index for that animal.
Generation of rat c-met and rat HGF-specific probes
Reverse transcriptase polymerase chain reaction (RT-PCR) was
carried out using the following nested primers based on the
published rat c-met sequence (Liu et al, 1996): forward primer 
(a): AACAACGTACGGTGTCTCCAG; reverse primer (b):
CAGGATAGGAATCCAGGAGGA. Poly-A+ RNA (1 mg) extracted
from rat liver was reverse-transcribed using AMV reverse
transcriptase (Boehringer Mannheim, Mannheim, Germany) in
conjunction with primer (b). Subsequent PCR amplification of the
first strand of cDNA was performed using primer (a) under the
following thermocycling regime; 1 cycle at 94°C for 5 min then 30
cycles at 94°C for 2 min, 60°C for 30 s, 72°C for 1 min and a final
step at 94°C/2 min, 60°C for 30 s, 72°C for 10 min. PCR products
were ligated into the pGEM-T vector (Promega, Madison, WI,
USA), and positive clones sequenced to confirm their identity in
comparison to the published rat c-met sequence.
The resultant rat c-met pGEM clone was linearized with SalI
and a 393 bp 32P-labelled antisense riboprobe generated with T7
polymerase using a Maxiscript transcription kit (Ambion, Austin,
TX, USA). Sense-strand riboprobe was generated by SP6 tran-
scription of the construct linearized with HaeIII. A human 18S
rRNA antisense riboprobe (Ambion) was also prepared for loading
control.
A rat HGF riboprobe was prepared by subcloning of an EcoRI
fragment of the rat HGF cDNA (provided by Professor T
Nakamura, Osaka, Japan) into pSP73 vector (Bresatec Ltd,
Adelaide, Australia) and subsequent linearization with HincII
before transcription with SP6 polymerase. The sense probe was
synthesized by transcription from the same linearized cDNA with
T7 polymerase.
Ribonuclease protection assays
Ribonuclease protection assays (RPA) were carried out to measure
changes in HGF and c-met gene expression using an Ambion RPA
II kit (Ambion). RNA was extracted from proximal jejunal tissues
using the RNA/DNA/Protein separation reagent (Progen
Industries, Brisbane, Australia). Total RNA (60 mg) was hybrid-
ized overnight at 45°C with a molar excess of radiolabelled anti-
sense HGF or c-met riboprobe together with 18 S probe. Hybrids
were subsequently digested with RNAase A+T1 for 30 min at
37°C and were run on 6% polyacrylamide gels before gels were
exposed for autoradiography for between 4 h (for 18S ribosomal
RNA signal) and 3 weeks (for HGF signal) at –80°C.
Densitometry of autoradiographs was carried out, and abundance
of the target gene was expressed as the ratio of the density value of
the protected target band over that of the 18S rRNA loading
control of the sample.
In situ hybridization detection of HGF and c-met mRNA
A non-radioactive in situ hybridization approach was used to
localize any changes in HGF and c-met mRNA expression during
the intestinal damage and repair. Digoxigenin (DIG)-labelled
sense and antisense riboprobes were generated similarly as for the
ribonuclease protection assays but using a DIG RNA labelling 
kit (Boehringer Mannheim). In situ hybridization was performed
on 4-mm paraffin sections of the proximal jejunum following 
a protocol as described (Zhou et al, 1999). Hybridization was
carried out for 18 h at 55°C with 0.5 mg ml–1 the sense or 
antisense probe. Hybridized probes were detected with an alka-
line phosphatase-coupled sheep anti-DIG IgG (Boehringer
Mannheim).Western blotting of HGF and c-met
To demonstrate potential changes in HGF and c-met expression at
the protein level, Western blotting was performed on total protein
samples isolated from the proximal jejunal tissues, the same
pieces of specimens used for total RNA extraction by the
RNA/DNA/Protein separation reagent as described above. Equal
amounts of protein (200 mg) from each sample, as quantitated
using Bradford Reagent (Sigma), and 2 mg of a broad range of
biotinylated protein molecular weight markers (Bio-Rad,
Hercules, CA, USA) were treated with a reducing sample buffer
(Laemmli, 1970), separated on a sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE) mini-gel (10% for
HGF, 7.5% for c-met), and electroblotted onto a 0.2 mm nitrocellu-
lose filter. For HGF gel, 200 ng of recombinant human HGF
(provided by Professor T Nakamura, Osaka, Japan) was used as a
standard. The filters were probed with a goat anti-human HGF IgG
(R&D Systems, Minneapolis, MN, USA), or a rabbit anti-mouse c-
met IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
were respectively incubated with a rabbit anti-goat biotinylated
IgG or a swine anti-rabbit biotinylated IgG (Dako). After incuba-
tion with avidin and biotinylated horseradish peroxidase reagents
(Dako), filters were developed for enzyme-chemiluminescence
signal using ECL reagents (Amersham, Buckinghamshire, UK).
Statistical analysis
Results of the villus height and crypt depth measurements (mm),
BrdU labelling (%) and RNA protection assays (% of day 0
control) between the groups of animals treated with methotrexate
and untreated normal controls were compared by one-way analysis
of variance using Fisher’s protected LSD test.
RESULTS
As we have observed in earlier studies (Howarth et al, 1996),
methotrexate treatment induced typical intestinal histological
damage profiles, with the most pronounced effect in the duodenum
and proximal jejunum, and least severe damage in the distal ileum.
In the proximal jejunum, methotrexate induced readily apparent
damage by day 3 (Figure 1B) and maximal damage by day 5
(Figure 1C). Some improvement was noted by day 6, followed by
a rapid recovery on day 7 (Figure 1D and Figure 2A). On day 5,
jejunal histology was characterized by crypt loss, villous atrophy,
fusion and shortening (Figure 1C). On day 6, the jejunum showed
marked crypt elongation and reduced villus height (Figure 2B).
The villi returned to normal height on day 7, lengthened on days 8
and 9, and then shortened gradually toward normality, post day 9.
Crypt depth declined on day 7 and normalized by day 11 (Figure
2B). To eliminate the possibility that the above histological
changes were a result of a reduced food intake following
methotrexate injection, groups of pair-fed rats without metho-
trexate injection were killed on day 5 and day 8 for comparison.
Histological analysis revealed normal intestinal villus height and
crypt depth in the pair-fed rats on days 5 and 8 (not shown), indi-
cating that the intestinal histological changes in the methotrexate-
injected animals did not result from a reduction in food intake, but
rather were a result of a direct effect of methotrexate on the
intestinal mucosa.
At the cellular level, a significant drop of crypt cell BrdU
labelling on day 3 (Figure 1 E, F and Figure 2C) preceded the
histological damage (villus shortening and some crypt loss) which
peaked on day 5. Conversely, an up-regulation of crypt cell prolif-
eration on days 5 and 6 (Figures 1G and 2C) occurred 1 or 2 days
prior to the elongation of crypts and villi (Figure 2B, C),
suggesting that a hyperproliferation of crypt cells led to the regen-
eration of the intestine.
To begin to examine the potential role of HGF during intestinal
regeneration following methotrexate-induced damage, mRNA and
protein expression of both HGF and receptor c-met was examined
in the proximal jejunal tissues throughout the methotrexate-
induced damage/repair time course. By ribonuclease protection
assay, expression of HGF mRNA in the intestine was found to be
very low compared to that of c-met, necessitating far longer expo-
sure of autoradiographs. This is evidenced by the much lower
expression level with normal jejunal RNA (day 0) compared to
that of liver RNA (used as a positive control for HGF expression)
(Figure 3A). However, the level of c-met mRNA was found to be
comparable in both tissues (liver data not shown). In the time
course study (Figure 3A) HGF mRNA was increased in the
jejunum on day 5 and day 6, a response that was statistically
significant in day 5 animals compared to the day 0 controls (P <
0.05) (Figure 3C). From day 7, the HGF mRNA level declined to
below the level of normal controls, with the decrease on day 8
being statistically significant (P < 0.05). By comparison, c-met
mRNA was increased from day 4 to day 8 with statistical signifi-
cance attained in each case (Figure 3B, 3C). Compared to HGF,
up-regulation of c-met mRNA was of greater magnitude, with the
peak increase in c-met observed on day 6, 175% of day 0 expres-
sion. From day 7, the c-met mRNA level began to decline, and had
almost reached to the normal control level by day 9 (Figure 3C).
In situ hybridization was employed in concert to localize the
changes in HGF and c-met mRNA expression within the jejunal
tissue during the damage/repair time course (Figure 4). Using
sense riboprobes as negative controls, very little signal was
observed (Figure 4A for HGF, Figure 4E for c-met). Using anti-
sense riboprobes, in the normal jejunum weak to moderate signal
was detected for both HGF (Figure 4B) and c-met (Figure 4F), the
majority of which was localized cytoplasmically to the intestinal
crypt (more on the luminal side than on the basolateral side) and
lower villus epithelium, with little or no signal in the villus tips,
confirming a previous in situ hybridization study for HGF (Wang
et al, 1994). Consistent with increases in mRNA quantitated by
ribonuclease protection assays, there were increases in both HGF
(Figure 4C) and c-met (Figure 4G) mRNA hybridization signals in
day 5 rats after methotrexate treatment. Expression appeared to be
localized evenly to all cell types throughout the crypt epithelium
and at lower levels in cells of the lower villus epithelium, as per
the normal intestine. On day 5 and 6, increased HGF (Figure 4D)
and c-met mRNA (Figure 4H) expression could also be seen in
immune cells (as judged by cell morphology) of the lamina
propria. However, the specific cell-types and biological implica-
tions of this expression remain to be determined.
Western blotting analysis was performed on the total protein
samples extracted from the tissue specimens used for the RNA
extraction. Under reducing conditions, tissue HGF as well as the
recombinant HGF standard were shown as the 70 kDa bands on
the Western blots probed with an antibody raised against the
70 kDa subunit (not shown). Comparisons of protein samples from
different animals throughout the time course (based on equal
loading of total protein per lane) revealed an up-regulation of HGF
HGF/c-met expression in small intestine mucositis 947
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Figure 1 Histopathological (H&E staining) and proliferative (BrdU labelling) features of proximal jejunum of rats during methotrexate-induced damage and
repair. (A and E) Normal jejunal histology and BrdU labelling respectively on day 0. (B and F) A partial damage of the jejunum and a significant decrease in
BrdU labelling in day 3 rats. (C and G) Severe mucosal damage and a marked up-regulation of BrdU labelling in the damaged jejunum on day 5. (D and H) Near
normal histology and normal BrdU labelling on day 7. (Scale bar in D, 100 mm, applies to A–D; bar in H, 35 mm, applies to E–H.)on days 4, 5 and 6 (Figure 5A illustrating a representative blot),
with the highest level (up to 225% of day 0 control) observed on
day 5 as estimated by densitometry (Figure 5C). Similarly,
Western blotting analyses for c-met under reducing conditions
(Figure 5B) revealed that the c-met protein, shown mainly as the
145 kDa band using an antibody raised against the 145 kDa
subunit (and to a lesser extent the 170 kDa band probably due to
incomplete reduction of proteins), increased in level from days 3 to
6 (Figure 5C), consistent with the increase in mRNA level as
measured by the ribonuclease protection assay.
HGF/c-met expression in small intestine mucositis 949
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labelling of the proximal jejunum during methotrexate-induced damage and
repair. (A) Semi-quantitative scoring of damage severity, showing the median
severity score (n = 8). (B) Villus height and crypt depth measurements
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Figure 3 Examination of HGF and c-met mRNA expression by
ribonuclease protection assays in the proximal jejunum during methotrexate-
induced damage and subsequent repair. Total proximal jejunal or liver RNA
(L) (60 mg) was hybridized with either HGF or c-met riboprobe, and hybrids
were digested with RNAase A + T1 and visualized by autoradiography after
being separated on 6% PAGE gels. An 18S rRNA probe was used to control
for loading. (A and B) Representative protection assays for HGF and c-met
respectively. (C) Quantitative analysis of results following densitometry of
autoradiographs. Results were normalized for loading relative to 18S rRNA
and expressed as a % of day 0 levels. Asterisks depict statistical differences
compared to the day 0 control (*P < 0.05; **P < 0.01)950 CJ Xian et al
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Figure 4 In situ hybridization detection of HGF and c-met mRNA in proximal jejunum in normal and methotrexate-damaged rats. (A and E) Negative controls
with HGF and c-met sense riboprobes. (B and F) Weak or moderate labelling signals (black in colour) of HGF and c-met mRNA respectively in the normal
jejunum. (C and G) More intense staining for HGF and c-met mRNA respectively in methotrexate-damaged jejunum (day 5). (D and H) A higher-power view of C
and G respectively. (Scale bar in A, 100 mm, applies to A, E; bar in C, 50 mm, applies to B, C, F, G; bar in D, 25 mm, applies to D, H)DISCUSSION
We have demonstrated that the intestinal mucositis induced by
chemotherapy drug methotrexate is an acute and transient process
of mucosal damage and regeneration. This process was found to be
characterized by an initial significant decrease in crypt cell prolif-
eration on day 3, preceding the histopathological features of crypt
loss, villus shortening and atrophy with the severity peaking on
day 5. The repair process commenced on day 4, when the crypt
cell proliferation had returned to the normal level, and accelerated
on days 5 and 6 as evidenced by marked up-regulation of crypt cell
production. The overshoot of crypt cell proliferation on days 5 and
6 preceded the crypt elongation which commenced on day 6
followed by increases in villus height beginning on day 7. Finally,
the regeneration continued after day 7 with normalization of crypt
depth and villus height, with the crypt depth returning to the
normal level by day 11. This study confirms the original findings
on the adverse side-effects of methotrexate as a chemotherapeutic
agent on intestinal epithelial renewal. Methotrexate exerts its toxi-
city by directly inhibiting DNA synthesis, leading to a reduction of
mitosis in the crypts and shortening of the villi (Trier, 1962;
Altmann, 1974), followed by proliferative recovery phase after the
damage (Taminiau et al, 1980).
Previous in vivo studies have demonstrated that HGF plays an
important role in gastric ulcer repair, and in vitro studies have
shown that HGF stimulates intestinal cell proliferation and restitu-
tion (Kinoshita et al, 1997; Goke et al, 1998; Nishimura et al,
1998). Despite these reports, limited in vivo studies have been
undertaken to investigate the role of HGF in intestinal growth and
repair (Kato et al, 1998). In the present study, we have demon-
strated up-regulation of both HGF and c-met during the repair of
the small intestinal mucosa following methotrexate-induced
damage in the rat, similar to that observed during the healing 
of gastric ulcers (Tsujii et al, 1994; Kinoshita et al, 1995;
Schmassmann et al, 1997b). The transient up-regulation in HGF
mRNA and protein from days 4 to 6, peaking on day 5 coincides
with the timing of hyperproliferation during the repair of the
intestine. Similarly, the levels of c-met protein and mRNA were
elevated from days 3 or 4 to 6 or 8, peaking on day 6. The coin-
cident timing of HGF up-regulation and crypt cell hyperprolifera-
tion strongly suggests an involvement of HGF in the stimulation of
crypt cell proliferation as a prelude to the intestinal mucosal regen-
eration. This finding is consistent with previous in vitro studies
reporting HGF to be a potent mitogen for intestinal epithelial cells
(Dignass et al, 1994; Fukamachi et al, 1994). Our study is also
consistent with in vivo studies demonstrating that exogenous HGF
increased intestinal mass and function after massive small bowel
resection (Kato et al, 1998). Furthermore, our in situ hybridization
showed a co-localization of HGF and c-met mRNA in the crypt
and lower villous epithelium in both the normal and regenerating
intestine and an up-regulation of staining intensity during the
repair phase, suggesting an autocrine or a paracrine mechanism of
action for HGF in crypt cell proliferation and possibly cell migra-
tion during maintenance and repair of intestinal epithelium.
A numbers of growth factors and cytokines have been impli-
cated in intestinal regeneration in various animal models of
intestinal damage, including transforming growth factor a and b
(Barnard et al, 1995; Dignass et al, 1996), insulin-like growth
factor (Howarth et al, 1998), intestinal trefoil factor (Poulsom,
1996) and keratinocyte growth factor (Farrell et al, 1998). In this
study, we observed a close histopathological resemblance between
the methotrexate-induced rat intestinal mucositis and the clinical
gut mucositis seen in chemotherapy patients, a close temporal
correlation between the upregulation of HGF and its receptor and
HGF/c-met expression in small intestine mucositis 951
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the hyperproliferative repair, and a co-localization of HGF and 
c-met mRNA to intestinal crypt epithelium. These results suggest
that HGF may play an important role in stimulating intestinal
repair after acute damage and might be therapeutically useful in
enhancing intestinal repair in clinical settings. Further studies,
which could include the use of specific inhibition of the action of
HGF or c-met by using neutralizing antibody, antisense RNA, or
HGF/c-met mutation or other approaches, need to be conducted to
test whether the HGF/c-met ligand/receptor system plays an essen-
tial role in mucosal cell proliferation in vivo during intestinal
repair. A recent report has shown that exogenous HGF increased
intestinal mass and function after massive small bowel resection
(Kato et al, 1998), supporting this potential role in intestinal repair.
ACKNOWLEDGEMENTS
This project was funded in part by a Cooperative Research Centre
grant from the Australian Government and a project grant (to CJX
and LCR) from the Australian National Health and Medical
Research Council (NHMRC). The authors thank C Mardell, 
J Cool, D Tran and C Tran for technical assistance.
REFERENCES
Altmann GG (1974) Changes in the mucosa of the small intestine following
methotrexate administration or abdominal X-irradiation. Am J Anat 140:
263–280
Barnard JA, Beauchamp RD, Russell WE, Dubois RN and Coffey RJ (1995)
Epidermal growth factor-related peptides and their relevance to gastrointestinal
pathophysiology. Gastroenterology 108: 564–580
Costa G and Donaldson SS (1979) Current concepts in cancer. Effects of cancer and
cancer treatment on the nutrition of the host. N Engl J Med 300: 1471–1474
Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P,
Zara P and Comoglio PM (1991) Expression of the Met/HGF receptor in
normal and neoplastic human tissues. Oncogene 1997: 2003
Dignass AU, Lynch-Devaney K, Podolsky DK (1994) Hepatocyte growth
factor/scatter factor modulates intestinal epithelial cell proliferation and
migration. Biochem Biophys Res Commun 202: 701–709
Dignass AU, Stow JL and Babyatsky MW (1996) Acute epithelial injury in the rat
small intestine in vivo is associated with expanded expression of transforming
growth factor a and b. Gut 38: 687–693
Donaldson SS and Lenon RA (1979) Alterations of nutritional status: the impact of
chemotherapy and radiation therapy. Cancer 43 (Suppl.): 2036–2053
Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill
DC, Wiemann B, Starnes CO, Havill AM, Lu Z-N, Aukerman SL, Pierce GF,
Thomason A, Potten CS, Ulich TR and Lacey DL (1998) Keratinocyte growth
factor protects mice from chemotherapy and radiation-induced gastrointestinal
injury and mortality. Cancer Res 58: 933–939
Fox JG, Li X, Cahill RJ, Andruits K, Rustgi AK, Odze R and Wang TC (1996)
Hypertrophic gastropathy in Helicobacter felis-infected wild-type C57BL/6
mice and p53 homizygous transgenic mice. Gastroenterology 110: 155–166
Fukamachi F, Ichinose M, Tsukada S, Kakei N, Suzuki T, Miki K, Kurokawa K and
Masui T (1994) Hepatocyte growth factor specifically stimulates
gastrointestinal growth in primary culture. Biochem Biophys Res Commun 205:
1445–1451
Goke M, Kanai M and Podolsky DK (1998) Intestinal fibroblasts regulate intestinal
epithelial cell proliferation via hepatocyte growth factor. Am J Physiol 37:
G809–G818
Howarth GS, Francis GL, Cool JC, Xu X, Byard RW and Read LC (1996) Milk
growth factors enriched from cheese whey ameliorate intestinal damage by
methotrexate when administered orally to rats. J Nutr 126: 2519–2530
Howarth GS, Cool JC, Bourne AJ, Ballard FJ and Read LC (1998) Insulin-like
growth factor-I (IGF-I) stimulates regrowth of the damaged intestine in rats,
when administered following, but not concurrent with, methotrexate. Growth
Factors 15: 279–292
Jolivet J, Wowan JH, Curt GA, Clendennin NJ and Charner BA (1983) The
pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094–1104
Kato Y, Yu D and Schwartz MZ (1998) Enhancement of intestinal adaptation by
hepatocyte growth factor. J Pediatr Surg 33: 235–239
Kermorgant S, Walker F, Hormi K, Dessirier V, Lewin MJ and Lehy T (1997)
Developmental expression and functionality of hepatocyte growth factor and
c-Met in human fetal digestive tissues. Gastroenterology 112: 1635–1647
Kinoshita Y, Nakata H, Hassan S, Asahara M, Kawanami C, Matsushima Y,
Naribayashi-Inomoto Y, Ping CY, Min D, Nakamura A and Chiba T (1995)
Gene expression of keratinocyte and hepatocyte growth factors during the
healing of rat gastric mucosal lesions. Gastroenterology 109: 1068–1077
Kinoshita Y, Kishi K, Asahara M, Matsushima Y, Wang H-Y, Miyazawa K,
Kitamura N and Chiba T (1997) Production and activation of hepatocyte
growth factor during the healing of rat gastric ulcers. Digestion 58: 225–231
Laemmli UK (1970) Cleavage of the structural proteins during the assembly of the
head of the bacteriophage T4. Nature 227: 680–685
Liu YH, Tolbert EM, Sun AM and Dworkin LD (1996) Primary structure of rat HGF
receptor and induced expression in glomerular mesangial cells. Am J Physiol
40: F679–F688
Nishimura S, Takahashi M, Ota S, Hirano M and Hiraishi H (1998) Hepatocyte
growth factor accelerates restitution of intestinal epithelial cells.
J Gastroenterol 33: 172–178
Poulsom R (1996) Trefoil peptides. Bailli￿re￿s Clin Gastroenterol 10: 113–134
Prat M, Narshiman RP, Crepaldi T, Nicotra MR, Natali PG and Comoglio PM (1991)
The receptor encoded by the human c-met oncogene is expressed in
hepatocytes, epithelial cells and solid tumors. Int J Cancer 49: 323–328
Schmassmann A, Hirschi C, Stettler C, Poulsom R and Halter F (1997a) Recent
work with hepatocyte growth/scatter factor. In: The Gut as a Model in Cell and
Molecular Biology, Halter F, Winton D and Wright NA (eds), pp. 180–193.
Kluwer Academic Publishers: Lancaster
Schmassmann A, Stettler C, Poulsom R, Tarasova N, Hirschi C, Flogerzi B,
Matsumoto K, Nakamura T and Halter F (1997b) Roles of hepatocyte growth
factor and its receptor met during gastric ulcer healing in rats. Gastroenterology
113: 1858–1872
Takahashi M, Ota S, Hata Y, Ogura K, Kurita M, Terano A, Nakamura T and Omata
M (1996) Constitutive expression of hepatocyte growth factor may maintain
the sheet construction of gastric epithelial cells through facilitating actin-
myosin contractile system. Biochem Biophys Res Commun 214: 40–46
Taminiau JA, Gall DG and Hamilton JR (1980) Response of the rat small intestine
epithelium to methotrexate. Gut 21: 486–492
Trier JS (1962) Morphologic alterations induced by methotrexate in the mucosa of
human proximal intestine. Gastroenterology 42: 295–305
Tsujii M, Kawano S, Tsuji S, Ito T, Hayashi N, Horimoto M, Mita E, Nagano K,
Masuda E, Fusamoto H and Kamada T (1994) Increased expression of c-met
messenger RNA following acute gastric injury in rats. Biochem Biophys Res
Commun 200: 536–541
Wang Y, Selden C, Farnaud S, Calnan D and Hodgson HJF (1994) Hepatocyte
growth factor (HGF/SF) is expressed in human epithelial cells during
embryonic development; studies by in situ hybridisation and Northern blot
analysis. J Anat 185: 543–551
Wolf HK, Zarnegar R and Michalopoulos GK (1991) Localization of hepatocyte
growth factor in human and rat tissues: an immunohistochemical study.
Hepatology 14: 488–494
Zhou X-F, Deng YS, Chie ET, Xue Q, Zhong J-H, McLachlan EM, Rush RA and
Xian CJ (1999) Satellite cell-derived nerve growth factor or neurotrophin-3 are
involved in noradrenergic sprouting in the dorsal root ganglia following
peripheral nerve injury in the rat. Eur J Neurosci 11: 1711–1722